SCHEMBL4928107

SCHEMBL4928107

Cc1ccc(-c2ccccc2)c(N2Cc3c[nH]nc3-c3ccccc32)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 3/20 0.34
▸ LMNA P02545 2/20 0.34
▸ PDCD1 Q15116 2/20 0.33
▸ CD274 Q9NZQ7 2/20 0.33
▸ HTR7 P34969 2/20 0.33
▸ HTR1A P08908 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ HTR5A P47898 1/20 0.33
▸ HTR6 P50406 1/20 0.33
▸ TP53 P04637 2/20 0.32
▸ PTGDR2 Q9Y5Y4 1/20 0.32
▸ PSMB5 P28074 1/20 0.32
▸ NPC1 O15118 3/20 0.31
▸ RAB9A P51151 3/20 0.31
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ ADORA3 P0DMS8 2/20 0.31
▸ ADORA1 P30542 2/20 0.31
▸ NFKB1 P19838 1/20 0.31
▸ NFKB2 Q00653 1/20 0.31
▸ RELA Q04206 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4925608 0.74 L3MBTL1 (0.40) MAPTLMNANPC1RAB9APKM
SCHEMBL2703631 0.68 KCNN4 (0.57) MAPTLMNAHTR6L3MBTL1ALDH1A1
SCHEMBL3108967 0.65 TDP1 (0.52) MAPTLMNANPC1RAB9ASMN1; SMN2
SCHEMBL13021700 0.62 MGLL (0.44) MAPTLMNAHTR7HTR1AHTR2A
SCHEMBL13021774 0.62 MGLL (0.47) MAPTLMNAHTR7HTR1AHTR2A
SCHEMBL11621636 0.62 DCUN1D1 (0.41) NPC1RAB9ASMN1; SMN2L3MBTL1ALDH1A1
SCHEMBL28197453 0.60 ALOX15 (0.43) MAPTLMNARAB9AADORA3ADORA1
SCHEMBL25472802 0.60 NPC1 (0.38) MAPTLMNATP53NPC1RAB9A
SCHEMBL13021779 0.60 MGLL (0.45) LMNAHTR7HTR1AHTR2AHTR5A
SCHEMBL13022557 0.60 MGLL (0.45) MAPTLMNAHTR7HTR1AHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase ELAN PHARMACEUTICALS, INC. 2008-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021056-A1 Fused, Tricyclic Sulfonamide Inhibitors of Gamma Secretase BACE1, BACE2, PSEN1 MAPT 72/4885LMNA 1368/4885PDCD1 4399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback